Revenue

As AI tools flood the market, WPS Office is betting not on raw power but on invisibility. Its new update embeds AI and cloud sync to eliminate friction.

A new report ranks Changi Airport among the world's top carbon emitters, challenging Singapore's sustainable hub ambitions amid rising global pressure.

As 7.io expands, it champions crypto-native speed and fairness, but navigates a landscape fraught with regulatory risk and security challenges.

Nocpix enters the digital riflescope market with the NITE D70R, packing a 12MP sensor and integrated ballistics to challenge established industry leaders.

China's 'Dream Stream' at the Venice Biennale merges ancient philosophy with AI art, video games, and immersive installations in a stunning display.

Wondrlab is investing $100M in WondrBridge, a venture building small, AI-powered innovation hubs that challenge traditional outsourcing models.

A former oil refinery is being transformed into the Northeast's largest film studio, a $1B project poised to make New Jersey a new Hollywood East.

Glucotrack seeks FDA trial approval for its revolutionary 3-year implantable glucose monitor, racing against financial clocks to change diabetes care.

Amid major Medicare policy shifts, Nuo Therapeutics reports a 169% revenue surge, positioning its Aurix wound care system as a key market disruptor.

A new study finds a minimally invasive procedure provides greater short-term weight loss than a popular pill, reshaping the debate on obesity treatment.

The iconic American rib chain is back in China, but this is more than just a restaurant opening. It's a high-tech, high-stakes bet on the future.

Nubank's AI-first strategy drives record revenue and profitability in Mexico, but rising delinquencies test its advanced risk management models.

A Houston firm is set to make waves with a rare Modigliani drawing and a private Dalí painting, complete with personal letters from the artist.

As its CFO presents at a top NYC conference, Healios K.K. advances novel stem cell treatments for ARDS, stroke, and cancer into critical global trials.

Westaim posted a $33.4M Q1 loss, but strong early sales from its new annuity product suggest a long-term strategic transformation is taking root.

The Solana treasury firm reported a massive GAAP loss due to SOL's price drop, but it also secured new debt, bought back shares, and pushed into new markets.

Out of 600+ plans, Alignment Health is one of just four to earn a top award for medication quality. Here's what that means for seniors and the industry.

Figma's revenue growth accelerated to 46% in Q1, driven by the successful monetization of its AI tools and deepening enterprise adoption.

Boston Omaha posts higher revenue and operational cash flow, but a wider net loss driven by investment headwinds reveals a complex picture for investors.

Edesa Biotech pushes its pipeline forward with a new vitiligo trial and promising ARDS data, but rising R&D costs highlight the high stakes of innovation.